Effect of Nateglinide on the Incidence of Diabetes and
Cardiovascular Events

J 2010

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

HOLMAN, Rury R.; Steven M. HAFFNER; John J. MCMURRAY; M. A. BETHEL; B. HOLZHAUER et al.

Základní údaje

Originální název

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

Autoři

HOLMAN, Rury R.; Steven M. HAFFNER; John J. MCMURRAY; M. A. BETHEL; B. HOLZHAUER; T. A. HUA; Y. BELENKOV; M. BOOLELL; J. B. BUSE; B. M. BUCKLEY; A. R. CHACRA; F. T. CHIANG; B. CHARBONNEL; C. C. CHOW; M. J. DAVIES; P. DEEDWANIA; P. DIEM; D. EINHORN; V. FONSECA; G. R. FULCHER; Z. GACIONG; S. GAZTAMBIDE; T. GILES; E. HORTON; H. ILKOVA; T. JENSSEN; S. E. KAHN; H. KRUM; M. LAAKSO; L. A. LEITER; N.S. LEVITT; V. MAREEV; F. MARTINEZ; C. MASSON; T. MAZZONE; E. MEANEY; R. NESTO; C. Y. PAN; R. PRAGER; S. A. RAPTIS; G. RUTTEN; H. SANDSTROEM; F. SCHAPER; A. SCHEEN; O. SCHMITZ; I. SINAY; Vladimír SOŠKA; S. STENDER; G. TAMAS; G. TOGNONI; J. TUOMILEHTO; A. S. VILLAMIL; J. VOZAR a R. M. CALIFF

Vydání

New England Journal of Medicine, USA, MASSACHUSETTS MEDICAL SOC, 2010, 0028-4793

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 53.486

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051691

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1056/NEJMoa1001122

UT WoS

000276894700006

Klíčová slova anglicky

IMPAIRED GLUCOSE-TOLERANCE; RANDOMIZED CONTROLLED-TRIAL; PHASE INSULIN-SECRETION; 10-YEAR FOLLOW-UP; FASTING GLUCOSE; LIFE-STYLE; PREVENTION; MELLITUS; NIDDM; CLASSIFICATION

Příznaky

Mezinárodní význam

Změněno: 16. 4. 2012 09:39, Mgr. Michal Petr

Anotace

V originále

BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization. RESULTS: After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P=0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P=0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P=0.16). Nateglinide did, however, increase the risk of hypoglycemia. CONCLUSIONS: Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes.

Citovat

@article{919381,
   author = {Holman, Rury R. and Haffner, Steven M. and McMurray, John J. and Bethel, M. A. and Holzhauer, B. and Hua, T. A. and Belenkov, Y. and Boolell, M. and Buse, J. B. and Buckley, B. M. and Chacra, A. R. and Chiang, F. T. and Charbonnel, B. and Chow, C. C. and Davies, M. J. and Deedwania, P. and Diem, P. and Einhorn, D. and Fonseca, V. and Fulcher, G. R. and Gaciong, Z. and Gaztambide, S. and Giles, T. and Horton, E. and Ilkova, H. and Jenssen, T. and Kahn, S. E. and Krum, H. and Laakso, M. and Leiter, L. A. and Levitt, N.S. and Mareev, V. and Martinez, F. and Masson, C. and Mazzone, T. and Meaney, E. and Nesto, R. and Pan, C. Y. and Prager, R. and Raptis, S. A. and Rutten, G. and Sandstroem, H. and Schaper, F. and Scheen, A. and Schmitz, O. and Sinay, I. and Soška, Vladimír and Stender, S. and Tamas, G. and Tognoni, G. and Tuomilehto, J. and Villamil, A. S. and Vozar, J. and Califf, R. M.},
   article_location = {USA},
   article_number = {16},
   doi = {https://doi.org/10.1056/NEJMoa1001122},
   keywords = {IMPAIRED GLUCOSE-TOLERANCE; RANDOMIZED CONTROLLED-TRIAL; PHASE INSULIN-SECRETION; 10-YEAR FOLLOW-UP; FASTING GLUCOSE; LIFE-STYLE; PREVENTION; MELLITUS; NIDDM; CLASSIFICATION},
   language = {eng},
   issn = {0028-4793},
   journal = {New England Journal of Medicine},
   title = {Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events},
   volume = {362},
   year = {2010}
}

TY  - JOUR
ID  - 919381
AU  - Holman, Rury R. - Haffner, Steven M. - McMurray, John J. - Bethel, M. A. - Holzhauer, B. - Hua, T. A. - Belenkov, Y. - Boolell, M. - Buse, J. B. - Buckley, B. M. - Chacra, A. R. - Chiang, F. T. - Charbonnel, B. - Chow, C. C. - Davies, M. J. - Deedwania, P. - Diem, P. - Einhorn, D. - Fonseca, V. - Fulcher, G. R. - Gaciong, Z. - Gaztambide, S. - Giles, T. - Horton, E. - Ilkova, H. - Jenssen, T. - Kahn, S. E. - Krum, H. - Laakso, M. - Leiter, L. A. - Levitt, N.S. - Mareev, V. - Martinez, F. - Masson, C. - Mazzone, T. - Meaney, E. - Nesto, R. - Pan, C. Y. - Prager, R. - Raptis, S. A. - Rutten, G. - Sandstroem, H. - Schaper, F. - Scheen, A. - Schmitz, O. - Sinay, I. - Soška, Vladimír - Stender, S. - Tamas, G. - Tognoni, G. - Tuomilehto, J. - Villamil, A. S. - Vozar, J. - Califf, R. M.
PY  - 2010
TI  - Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
JF  - New England Journal of Medicine
VL  - 362
IS  - 16
SP  - 1463-1476
EP  - 1463-1476
PB  - MASSACHUSETTS MEDICAL SOC
SN  - 00284793
KW  - IMPAIRED GLUCOSE-TOLERANCE
KW  - RANDOMIZED CONTROLLED-TRIAL
KW  - PHASE INSULIN-SECRETION
KW  - 10-YEAR FOLLOW-UP
KW  - FASTING GLUCOSE
KW  - LIFE-STYLE
KW  - PREVENTION
KW  - MELLITUS
KW  - NIDDM
KW  - CLASSIFICATION
N2  - BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization. RESULTS: After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P=0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P=0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P=0.16). Nateglinide did, however, increase the risk of hypoglycemia. CONCLUSIONS: Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes.
ER  -

Přehled o publikaci